IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4411
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$1.5B
David Campbell
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$JANX Janux Therapeutics, Inc. | 32 | 43 | 44 | 8 | - | - | -11.2% | -10.7% | 100.0% | -4258.5% | -3317.3% | 12.4% | 0.0% | 5.0x | $1.5B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Janux Therapeutics, Inc. (JANX) receives a "Avoid" rating with a composite score of 31.6/100. It ranks #4411 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for JANX.
View All RatingsROE proxy -11.2% (sector -1.9%)
GM 100% vs sector 44%, OM -4258% vs sector 3%
Capital turnover N/A, R&D intensity 943.5%
Rev growth 12%, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Janux Therapeutics, Inc. (JANX) as Avoid with a composite score of 31.6/100 at a current price of $13.38. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Janux Therapeutics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 31.6/100 places it at rank #4411 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 100% signal strong pricing power.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
Janux Therapeutics, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Janux Therapeutics, Inc. with an Avoid rating, assigning a composite score of 31.6/100 and 1 out of 5 stars. Ranked #4411 of 7,333 stocks, JANX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
JANX's quality score of 43/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -11.2% (sector avg: -1.9%), gross margins of 100.0% (sector avg: 44.1%), net margins of -3317.3% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 44/100, JANX appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 0.81x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Janux Therapeutics, Inc.'s investment score of 21/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 12.4% vs. a sector average of 6.7% and a return on assets of -10.7% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Janux Therapeutics, Inc. is experiencing notably weak momentum with a score of just 8/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 12.4% year-over-year, while a beta of 1.20 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
JANX's stability score of 37/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.20 and a debt-to-equity ratio of 5.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Janux Therapeutics, Inc.'s short interest score of 27/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.20), elevated leverage (D/E: 5.00x), small-cap liquidity risk. At $1.5B (small-cap), JANX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Janux Therapeutics, Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4411 of 7,333 overall (40th percentile). Key comparisons include ROE of -11.2% trailing the -1.9% sector median and operating margins of -4258.5% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While JANX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (8) would have the largest impact on the composite score.
ROE 492% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 127% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 169761% BELOW SECTOR MEDIAN
Janux Therapeutics and Bristol Myers have announced a deal worth up to $850 million for the development of a cancer drug. This agreement highlights a strategic collaboration between the two companies in the field of oncology. The news was reported by Reuters.
Clear Str downgraded Janux Therapeutics (NASDAQ:JANX) from "strong-buy" to "hold" as several other analysts also cut price targets, though the consensus remains a "Moderate Buy" with a $60.08 average target. Despite beating last quarter's EPS and revenue estimates, analysts forecast a negative EPS for the current fiscal year. Insider selling, including by the CEO, adds to the negative sentiment surrounding the company.
Clear Street downgraded Janux Therapeutics (NASDAQ:JANX) from Buy to Hold, significantly reducing its price target to $12.00 from $32.00, due to concerns about the efficacy and durability of its cancer treatment platform, JANX007. The firm believes it's highly unlikely JANX007 will meet the median radiographic progression-free survival benchmark established by PLUVICTO. This downgrade follows Janux's recent Phase 1a and 1b trial reports, which also prompted various other analysts to adjust their ratings and price targets for JANX.
Janux Therapeutics VP Maria Dobek sold 1,462 shares of the company's stock on January 2nd, reducing her ownership by 8.68%. The transaction totaled $20,073.26 with shares sold at an average price of $13.73. Following the sale, Dobek now owns 15,373 shares valued at approximately $211,071.29.
Andrew Hollman Meyer sold 1,879 shares of Janux Therapeutics (NASDAQ:JANX) stock on January 2nd for over $25,000, reducing his stake by 2.21%. This transaction is part of broader insider selling activity at Janux Therapeutics, with multiple executives, including CEO David Alan Campbell, also selling shares. Despite the insider selling, analysts maintain a "Moderate Buy" consensus rating for JANX, though several firms have recently lowered their price targets.
Above 50MA
37.18%
Net New Highs
+51081